10 July, 2023 in Investor Relations Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury
01 June, 2023 in Investor Relations Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin’s tACS Devices in the Asia Pacific Region
24 January, 2023 in Investor Relations Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory
14 November, 2022 in Investor Relations Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder
20 September, 2022 in Investor Relations Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering
15 September, 2022 in Investor Relations Nexalin Technology, Inc. Announces Pricing of $9.6 Million Initial Public Offering